by The SARM1 Inhibitors Market comprises pharmaceutical agents that target and block the SARM1 protein, which plays a key role in amplifying neuronal damage caused by neurodegenerative conditions like amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). By inhibiting this protein, SARM1 drugs aim to slow down or stop neurodegeneration, protecting neurons from premature death.
The SARM1 Inhibitors Market is estimated to be valued at US$ 5 Mn in 2024 and is expected to exhibit a CAGR of 103% over the forecast period 2024-2031.
Key Takeaways
Key players operating in the SARM1 Inhibitors Market are Disarm Therapeutics, Nura Bio, Washington University, Asha Therapeutics, and UCB Pharma. Disarm Therapeutics is one of the leading players in this domain, developing DNL788 as the first clinical candidate to target SARM1 for neurodegeneration. The company has ongoing clinical trials evaluating DNL788 for ALS.
The growing burden of neurodegenerative diseases globally is fueling the demand for novel treatment strategies targeting various pathways involved in neuronal damage and death. As SARM1 inhibition is showing tremendous potential in preclinical research, it is attracting significant investments from pharmaceutical companies and venture capital firms.
Several biotechs are expanding their R&D footprint in multiple geographies to tap the unmet need for neuroprotection therapy. For instance, Asha Therapeutics raised $45 million in Series A funding in 2022 to advance its SARM1 programs and set up new research centers in Europe and Asia to accelerate drug development.
Market Key Trends
One of the major trends in the SARM1 Inhibitors Market is its focus on less common neurological disorders beyond ALS and MS. While initial research involves evaluating SARM1 drugs for these major indications, companies are exploring the role of SARM1 activation in other diseases like frontotemporal dementia, traumatic brain injury, and stroke. If proven effective, SARM1 inhibitors could become relevant for a wider patient pool suffering from various forms of neurodegeneration.
Porter’s Analysis
Threat of new entrants: Low costs to enter market but high costs required for R&D to develop new SARM1 inhibitor drugs.
Bargaining power of buyers: Large pharmaceutical buyers can negotiate low prices but development of new treatment options provides buyers less bargaining power.
Bargaining power of suppliers: Few suppliers currently operating in market but buyers have alternatives to consider so suppliers’ bargaining power is moderate.
Threat of new substitutes: Potential new therapies could displace SARM1 inhibitors depending on safety and efficacy compared to current options.
Competitive rivalry: Competition expected to intensify as more companies develop SARM1 inhibitors targeting large patient populations with neurological diseases.
Geographical Regions
North America currently dominates the SARM1 Inhibitors Market in terms of value as major players like Disarm Therapeutics and Nura Bio are based in the US and conducting clinical trials. Increased healthcare expenditures and greater adoption of novel drugs for neurodegenerative conditions contribute to North America’s large share of the market.
The Asia Pacific region is poised to experience the fastest growth over the forecast period from 2024 to 2031. Rising geriatric populations, growing healthcare investments, and an increasing focus on developing treatments for diseases like amyotrophic lateral sclerosis (ALS) are expected to spur market expansion in China, Japan, and other Asia Pacific countries.
Europe has a significant share of the SARM1 Inhibitors Market value due to presence of pharmaceutical companies doing research and a strong pipeline of drug candidates undergoing clinical testing. Countries with large biopharma industries like the UK, Germany, and France are major European markets for SARM1 inhibitors.
The Middle East and Africa region’s market is still in early development stages but growing research collaborations between academia and companies offer potential for market growth over the coming years. Increased recognition of neurological conditions and their burden could stimulate greater focus on and adoption of emerging therapies like SARM1 inhibitors.
What Are The Key Data Covered In This SARM1 Inhibitors Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the SARM1 Inhibitors’s growth between 2024 and 2031.
:- Accurate calculation of the size of the SARM1 Inhibitors and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- SARM1 Inhibitors Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market’s competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of SARM1 Inhibitors vendors
FAQ’s
Q.1 What are the main factors influencing the SARM1 Inhibitors?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top SARM1 Inhibitors companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the SARM1 Inhibitors’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
About Author - Vaagisha Singh
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. LinkedIn
